Azagly-nafarelin

Azagly-nafarelin

Clinical data
Trade names	Gonazon
Other names	6-[3-(2-Naphthalenyl)-D-alanine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide; 6-[3-(2-Naphthalenyl)-D-alanine]-10-deglycinamide-luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide
Routes of administration	Implant; Injection
Drug class	GnRH agonist
Identifiers
IUPAC name (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-indol-3-yl)methyl)-1,1-diamino-6-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-5-yl)-9-isobutyl-12-(naphthalen-2-ylmethyl)-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacos-1-en-24-yl)-5-oxopyrrolidine-2-carboxamide
CAS Number	91991-07-0 Y 113962-45-1 (acetate)
UNII	2N7D33X56N
CompTox Dashboard (EPA)	DTXSID30873507
Chemical and physical data
Formula	C65H82N18O13
Molar mass	1323.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C[C@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]1CCC(N1)=O)=O)CC2=CN=CN2)=O)CC3=CNC4=CC=CC=C43)=O)CO)=O)CC5=CC=C(O)C=C5)=O)CC6=CC7=CC=CC=C7C=C6)=O)C(N[C@H](C(N8CCC[C@H]8C(NNC(N)=O)=O)=O)CCC/N=C(N)\N)=O)C
InChI InChI=1S/C65H82N18O13/c1-35(2)25-47(56(88)74-46(13-7-23-70-64(66)67)63(95)83-24-8-14-53(83)62(94)81-82-65(68)96)75-58(90)49(28-37-15-18-38-9-3-4-10-39(38)26-37)76-57(89)48(27-36-16-19-42(85)20-17-36)77-61(93)52(33-84)80-59(91)50(29-40-31-71-44-12-6-5-11-43(40)44)78-60(92)51(30-41-32-69-34-72-41)79-55(87)45-21-22-54(86)73-45/h3-6,9-12,15-20,26,31-32,34-35,45-53,71,84-85H,7-8,13-14,21-25,27-30,33H2,1-2H3,(H,69,72)(H,73,86)(H,74,88)(H,75,90)(H,76,89)(H,77,93)(H,78,92)(H,79,87)(H,80,91)(H,81,94)(H4,66,67,70)(H3,68,82,96)/t45-,46-,47-,48-,49+,50-,51-,52-,53-/m0/s1 Key:FDOMSRGNWHJMGI-XRSSZCMZSA-N

Azagly-nafarelin, sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe. It is a GnRH analogue and a synthetic peptide, specifically a decapeptide. The medication has been approved in Europe as a solid silicone-based matrix implant for use as a contraceptive in animals such as male dogs, cats, and others, but is no longer or was never commercially available. The medication has also been used to treat benign prostatic hyperplasia in animals. In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ovulation in salmonids, and was the first GnRH agonist to be available for use in fish. It was introduced for use by 2005.

See also

• Gonadotropin-releasing hormone receptor § Agonists